| Literature DB >> 33807558 |
Akashi Fujita1, Shomei Ryozawa1, Masafumi Mizuide1, Yuki Tanisaka1, Tomoya Ogawa1, Masahiro Suzuki1, Hiromune Katsuda1, Yoichi Saito1, Tomoaki Tashima1, Kazuya Miyaguchi1, Eiichi Arai2, Tomonori Kawasaki2, Yumi Mashimo1.
Abstract
Currently, endoscopic ultrasound (EUS) has become widely accepted and has considerable advantages over computed tomography (CT) and other imaging modalities, given that it enables echostructure assessment in lesions with <1 cm diameter and permits high resolution imaging. EUS-guided tissue acquisition (EUS-TA) provides consistent results under ultrasound guidance and has been considered more effective compared to CT- or ultrasound-guided lesion biopsy. Moreover, complication rates, including pancreatitis and bleeding, have been extremely low, with <1% morbidity and mortality rates, thereby suggesting the exceptional overall safety of EUS-TA. The aggressive use of EUS for various lesions has been key in facilitating early diagnosis and therapy. This review summarizes the diagnostic ability of EUS for pancreatic solid lesions, subepithelial lesions, and lymph nodes where it is mainly used. EUS has played an important role in diagnosing these lesions and planning treatment strategies. Future developments in EUS imaging technology, such as producing images close to histopathological findings, are expected to further improve its diagnostic ability. Moreover, tissue acquisition via EUS is expected to be used for precision medicine, which facilitates the selection of an appropriate therapeutic agent by increasing the amount of tissue collected and improving genetic analysis.Entities:
Keywords: diagnostic accuracy; endoscopic ultrasound; endoscopic ultrasound-guided fine-needle aspiration; fine-needle biopsy; lymph nodes; lymphadenopathy; pancreatic solid lesions; subepithelial lesions
Year: 2021 PMID: 33807558 PMCID: PMC7961381 DOI: 10.3390/jcm10051076
Source DB: PubMed Journal: J Clin Med ISSN: 2077-0383 Impact factor: 4.241